Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 10:13 AM ET

Life Sciences Tools and Services

Company Overview of Accelovance, Inc.

Company Overview

Accelovance, Inc., a contract research organization (CRO), provides site management organization, patient recruitment, and clinical call center services. The company focuses on oncology, vaccines, and general medicine to pharmaceutical and biotech industries. Its CRO services include protocol development, project management, clinical trial monitoring, data management, biostatistics, pharmacovigilance, regulatory affairs, and medical writing services. The company also provides clinical call center services, such as recruitment/retention/compliance, post approval safety studies, phase IV studies, surveillance programs, patient-reported outcomes, observational studies, registries, site support ...

2275 Research Boulevard

Suite 700

Rockville, MD 20850

United States

Founded in 2004

Phone:

240-238-4900

Fax:

240-238-4901

Key Executives for Accelovance, Inc.

Founder, Chief Executive Officer and President
Age: 61
Chief Financial Officer
Senior Vice President of Clinical Development
Chief Medical Officer
Managing Director of Accelovance Europe
Compensation as of Fiscal Year 2015.

Accelovance, Inc. Key Developments

Panacea Pharmaceuticals, Inc. Engages Accelovance, Inc. for Clinical Development of its Novel Nanoparticle-Based Therapeutic Cancer Vaccine

Panacea Pharmaceuticals, Inc. and Accelovance Inc. announced the establishment of a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Through this agreement, Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory expertise, in addition to providing Contract Research Organization (CRO) support through Project Management, Clinical Monitoring, Data Management, Biostatistics, and Safety services for Panacea's clinical trials. The Panacea and Accelovance partnership will bring together highly complementary capabilities to advance and expedite Panacea's drug development and clinical advancement. Under the agreement, Panacea will maintain stringent oversight and quality standards relating to patient safety and regulatory compliance, with Accelovance assisting with the development and implementation of clinical strategies. Panacea will rely on Accelovance's knowledge in the areas of vaccines, oncology, and clinical management. Providing advanced insight into Panacea's development pipeline will enable both organizations to enhance operational planning, consistency, and execution.

Accelovance, Inc. Appoints Joseph D. Purvis as Vice President of Medical Affairs, Oncology

Accelovance, Inc. announced that Dr. Joseph D. Purvis has joined the company as Vice President Medical Affairs, Oncology. Dr. Purvis brings more than 25 years of oncology drug development experience to Accelovance, having provided significant contribution in the development, approval, and postmarketing development of multiple cytotoxic, biological, targeted, and hormonal products; including: IV Alkeran, IV Zyloprim, Navelbine, Eloxatin, Nolvadex, Faslodex, Arimidex, Casodex, Iressa, and Torisel. He has extensive regulatory experience, especially with the FDA and EMA, and has worked with community and academic oncologists and oncology cooperative groups. Dr. Purvis is an alumnus of Haverford College and of Jefferson Medical College. Dr. Purvis will be based in Accelovance's Raleigh Durham, NC office.

Accelovance Announces Opening of Research Triangle Park, North Carolina Office

Accelovance announced the opening of a new office in Research Triangle Park (RTP), North Carolina. This office opening supports continued corporate expansion and provides Accelovance's clients and employees with a presence in the research-active landscape of the RTP area of North Carolina. The new offices are close to many current and potential clients and offer a rich base of technical talent to support continued corporate growth. Accelovance plans to add up to 15 new clinical operations positions in the RTP area in 2014.

Similar Private Companies By Industry

Company Name Region
Theorem Clinical Research Inc. United States
UVP, LLC United States
Protedyne Inc. United States
Summit Drug Development Services LLC United States
Devices for Vascular Intervention Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 5, 2015
Altair Clinical Limited
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Accelovance, Inc., please visit www.accelovance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.